Concepedia

Bradley Heidrich

BH

Statistics

Publications

4

Citations

166

H-Index

4

Active since

2007

Affiliations

Janssen (United States)(Current)

GlaxoSmithKline (United States)

Bradley Heidrich is an author at Janssen (United States) specializing in medicine, oncology, and acute myeloid leukemia therapy.

Publications per year

2007–2020

4

Publications

4

Abstract B88: A selective Raf kinase inhibitor induces cell death and tumor regression of human cancer cell lines encoding B-RafV600E mutation

Sylvie Laquerre, Marc R. Arnone, Katherine G. Moss et al. · Molecular Cancer Therapeutics · 2009 · 54 citations

, , +15

A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia

Priyanka Nair-Gupta, Michael Diem, Dara Reeves et al. · Blood Advances · 2020 · 43 citations · Full text

, , +17

Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor

Douglas G. Johns, Zhaohui Ao, Bradley Heidrich et al. · Biochemical and Biophysical Research Communications · 2007 · 38 citations

, , +6

Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment

Priyanka Nair-Gupta, Stephen I. Rudnick, Leopoldo Luistro et al. · Blood Cancer Journal · 2020 · 31 citations · Full text

, , +17

1–4 of 4